Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 5/20 | 0.52 |
| ▸ | USP10 | Q14694 | 2/20 | 0.52 |
| ▸ | USP7 | Q93009 | 1/20 | 0.46 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680671 | 0.89 | HSPB1 (0.56) | HSPB1USP10USP7USP47L3MBTL1 | |
| SCHEMBL1364828 | 0.80 | USP10 (0.54) | USP10L3MBTL1TDP1VCAM1ALDH1A1 | |
| SCHEMBL2680991 | 0.78 | TDP1 (0.63) | USP10USP7USP47TDP1ALDH1A1 | |
| SCHEMBL15770914 | 0.78 | HSPB1 (0.51) | HSPB1L3MBTL1ATMTDP1ALDH1A1 | |
| SCHEMBL2681306 | 0.78 | USP7 (0.77) | USP10USP7USP47ATMTDP1 | |
| SCHEMBL4851442 | 0.77 | TDP1 (0.65) | HSPB1L3MBTL1ATMTDP1ALDH1A1 | |
| SCHEMBL21436430 | 0.77 | USP10 (0.65) | USP10USP47TDP1VCAM1ALDH1A1 | |
| SCHEMBL31371566 | 0.76 | HSPB1 (0.52) | HSPB1L3MBTL1ATMTDP1ALDH1A1 | |
| SCHEMBL5261995 | 0.74 | HSPB1 (0.56) | HSPB1L3MBTL1ATMTDP1ALDH1A1 | |
| SCHEMBL15067957 | 0.74 | HSPB1 (0.47) | HSPB1L3MBTL1ATMTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680139-B2 | Anti-neoplastic compounds, compositions and methods | PROGENRA (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA | 2012-05-10 | — | — | US | disclosed |
| WO-2010114881-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | PROGENRA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114765-A1 | ANTI-NEOPLASTIC COMPOUNDS, COMPOSITIONS AND METHODS | SERPINB1, TP53, CTSE | HSPB1 349/4885USP10 363/4885USP7 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.